Contact Information

Cellular Immunotherapy Program

Email: MGHCIP@mgh.harvard.edu

Support the Cellular Immunotherapy Program

Your support can help advance the research and development of promising cellular therapies that can harness the immune system to fight cancer. Make gift.

Explore the Cellular Immunotherapy Program

Overview

The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells. Our approach is to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects. We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies, with the ultimate goal of developing curative treatments for cancer and other diseases.

Our objectives:

We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies.

  • Bring together clinical researchers who administer, manage, and/or investigate immune effector cells as a therapeutic modality
  • Enable translational research and collaboration
  • Optimize immune monitoring and laboratory correlatives of clinical observations
  • Promote cellular therapy education through education sessions
  • Provide high quality care and management of patients receiving cellular therapies
  • Obtain and maintain FACT accreditation for the administration of immune effector cells
  • Invent and develop novel forms of cellular engineering that will become the next generation of immune cell therapies

Clinical Trials

View Cellular Therapy clinical trials.

CAR T-Cell Therapies

Mass General Cancer Center is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma (Breyanzi, Kymriah, Tecartus and Yescarta) and for adult patients with multiple myeloma (Abecma). Learn more.

TIL Therapy for Melanoma

Mass General Cancer Center is one of the first centers nationwide that offers FDA-approved Iovance TIL therapy (lifileucel) for patients with metastatic melanoma. Learn more.

CAR-T Therapy for Glioblastoma: INCIPIENT Clinical Trial

A research team from the Mass General Cancer Center recently conducted an early-stage trial of a new cell therapy for patients with recurrent glioblastoma. Preliminary results have shown remarkable initial responses among the first patients to receive the novel treatment. Learn more about the trial here and here.

If you are interested in learning more about the INCIPIENT clinical trial, please call 617-724-6226 or email carteamingbm@mgb.org. A member of our clinical team will contact you within 48 business hours.

Videos

A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.

Gene therapy offers durable treatments that modify defective genetic material to combat disease, while cell therapy involves the transplantation of healthy cells to repair or replace damaged tissue. Together, these therapies aim to restore proper cellular and genetic functions.

Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.

Of the many different approaches to activate the body’s immune system against cancer, CAR T-cell therapy is one of the most high tech and powerful treatments.

Marcela V. Maus, MD, PhD, Director of the Cellular Immunotherapy Program at the Mass General Cancer Center, was awarded a 2017 Stand Up to Cancer Innovative Research Grant for her work on "Potentiating Novel Engineered Cellular Therapies for Solid Tumors."

Kiss 108 FM’s Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-cell therapy is and what impact it has on both patients and the medical community.

Kiss 108 FM’s Billy Costa gets a doctor’s perspective of CAR T-cell therapy with Mass General Cancer Center’s clinical director for the Center of Lymphoma, Dr. Jeremy Abramson.

Kiss 108 FM’s Billy Costa sits down with Dr. Marcela Maus, director of cellular immunotherapy at the Mass General Cancer Center, and discusses what CAR T-cell therapy is, who is eligible for treatments, and the future direction of CAR T-cell therapy.

Kiss 108 FM’s Billy Costa discusses CAR T-cell therapy with Mass General Cancer Center’s Dr. Matthew Frigault, medical oncologist and administrative director for Cellular Therapy Services, who explains how this therapy has the potential to impact patients in immense ways.

Watch how Mass General patient Jenn Gilmann has already benefited from immunotherapy.

1 of 10

Resources

Gene and Cell Therapy Institute

Gene and Cell Therapy Institute

Learn how gene and cell therapy research at Mass General Brigham is rapidly advancing.

Maus Lab

Maus Lab

Visit the Maus laboratory, view publications and meet the team.

CAR T-Cell Therapies

CAR T-Cell Therapies

View CAR T-Cell Therapies.

TIL Therapy

TIL Therapy

Mass General is one of the first centers to offer TIL therapy for pts with melanoma.

Severe Immunotherapy Complications Service

Severe Immunotherapy Complications Service

Learn about Mass General's Severe Immunotherapy Complications Service.

Immune Monitoring Lab

Immune Monitoring Lab

Learn about the Immune Monitoring laboratory.

Cellular Therapy & Transplantation Lab

Cellular Therapy & Transplantation Lab

Learn about the Cellular Therapy & Transplantation Laboratory.

FACT Standards

FACT Standards

FACT Standards for Immune Effector Cells.

FACT information

FACT information

The why, what, and how of the new FACT standards for immune effector cells.

Gene and Cell Therapy Institute (GCTI)

The GCTI at Mass General Brigham is a hub of innovation & collaboration, uniting researchers & clinicians dedicated to advancing gene & cell therapy.

Learn about the GCTI

Krantz Family Center for Cancer Research

The scientific engine for discovery for the Mass General Cancer Center.

Learn more